Literature DB >> 3533365

The thalidomide syndrome: risks of exposure and spectrum of malformations.

C G Newman.   

Abstract

Echos of the 1959 to 1961 thalidomide disaster are still with us in the form of the continuing appearance, although more rarely, of similarly malformed children. A teratologic timetable could be fashioned retrospectively, supporting the concept that different body parts and systems have periods of vulnerability and of resistance to thalidomide, probably the most potent primate teratogen known. Something between one in every two to one in every ten fetuses exposed at the critical development period were affected. The clinical affects are described from the literature on approximately 2500 children, and from extensive personal experience, and a complex though finite pattern of malformations is described, indistinguishable from sporadic nonthalidomide cases of malformations that continue to occur.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3533365

Source DB:  PubMed          Journal:  Clin Perinatol        ISSN: 0095-5108            Impact factor:   3.430


  21 in total

Review 1.  Drug-induced congenital defects: strategies to reduce the incidence.

Authors:  M De Santis; B Carducci; A F Cavaliere; L De Santis; G Straface; A Caruso
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Recognition of thalidomide defects.

Authors:  R W Smithells; C G Newman
Journal:  J Med Genet       Date:  1992-10       Impact factor: 6.318

Review 3.  Thalidomide embryopathy: a model for the study of congenital incomitant horizontal strabismus.

Authors:  M T Miller
Journal:  Trans Am Ophthalmol Soc       Date:  1991

4.  Phocomelia and additional anomalies in two sisters.

Authors:  A Schinzel
Journal:  Hum Genet       Date:  1990-05       Impact factor: 4.132

5.  Robotic assisted radical prostatectomy for localised prostate cancer in thalidomide generation.

Authors:  Venkata Ramana Murthy Kusuma; Annelisse Ashton; Dimitrios Moschanos; Krishna Patil; Matthew Perry
Journal:  J Robot Surg       Date:  2017-08-28

6.  Beauty product-related exposures and childhood brain tumors in seven countries: results from the SEARCH International Brain Tumor Study.

Authors:  J T Efird; E A Holly; S Cordier; B A Mueller; F Lubin; G Filippini; R Peris-Bonet; M McCredie; A Arslan; P Bracci; S Preston-Martin
Journal:  J Neurooncol       Date:  2005-04       Impact factor: 4.130

7.  Pleiotropic patterning response to activation of Shh signaling in the limb apical ectodermal ridge.

Authors:  Chi-Kuang Leo Wang; Mizuyo H Tsugane; Victoria Scranton; Robert A Kosher; Louis J Pierro; William B Upholt; Caroline N Dealy
Journal:  Dev Dyn       Date:  2011-04-04       Impact factor: 3.780

8.  Can we ensure the safe use of known human teratogens? Introduction of generic isotretinoin in the US as an example.

Authors:  Margaret A Honein; Cynthia A Moore; J David Erickson
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  Thalidomide and the Titanic: reconstructing the technology tragedies of the twentieth century.

Authors:  G J Annas; S Elias
Journal:  Am J Public Health       Date:  1999-01       Impact factor: 9.308

Review 10.  Thalidomide and its derivatives: emerging from the wilderness.

Authors:  J N Gordon; P M Goggin
Journal:  Postgrad Med J       Date:  2003-03       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.